The ADAPT-TN-IV trial has the potential to redefine treatment protocols for high-risk triple-negative breast cancer (TNBC), which could significantly impact market dynamics. Success in this trial may enhance the competitive positioning of Sacituzumab Govitecan, challenging the current standard of care established by the KEYNOTE-522 trial. Regulatory context from FDA (FDA AP — INQOVI (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (6 high-relevance).